Torrent Pharma Approves FY26 Results, Recommends ₹9 Dividend & ₹5,000 Cr QIP.
Torrent Pharmaceuticals Limited reported audited financial results for FY26. The company recommended a final dividend of ₹9 per share and proposed a QIP of up to ₹5,000 crores. Revenue from operations for FY26 was ₹10,712 crores, with a net profit of ₹2,192 crores. The record date for the dividend is May 29, 2026.
The proposed QIP of ₹5,000 crores and the recommended dividend are material events that can significantly impact the company's financial structure and shareholder value.
The company reported positive financial results, recommended a substantial dividend, and proposed a significant equity fundraising, indicating confidence in future growth.
Torrent Pharmaceuticals Limited announced its audited financial results for the quarter and year ended March 31, 2026. The company's Board of Directors also recommended a final dividend of ₹9 per equity share (180%) and proposed seeking enabling approval for a Qualified Institutional Placement (QIP) of up to ₹5,000 crores at the upcoming Annual General Meeting (AGM).
The Board meeting, held on May 22, 2026, concluded with the approval of both standalone and consolidated financial results. The company has fixed Friday, May 29, 2026, as the record date for the proposed final dividend, which is expected to be paid on or around June 25, 2026. An interim dividend of ₹29 per equity share was already paid during the previous quarter.
The financial results indicate a revenue from operations of ₹2,735 crores for the quarter ended March 31, 2026, and ₹10,712 crores for the full year ended March 31, 2026. The net profit for the quarter stood at ₹467 crores, with the full year net profit at ₹2,192 crores. The company also disclosed its acquisition of a controlling stake in JB Pharma, with the scheme of amalgamation now filed with the National Company Law Tribunal (NCLT).
What to do with a filing like this
Torrent Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Torrent Pharmaceuticals Limited. Read the original for the full detail.